To test the conjecture that GCN2 compensates for PERK inactivation and to explore further the mechanism for PERK regulation, we investigated the effects of the chemotherapeutic drugs on PERK and GCN2 signalling in the drug sensitive and resistant MCF-7 breast cancer cells. This evidence concerns the gene EIF2AK4 and breast carcinoma.